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Abstract: The gamma-hydroxybutyric acid (GHB) withdrawal syndrome can have a fulminant
course, complicated by severe complications such as delirium or seizures. Detoxification by tapering
with pharmaceutical GHB is a safe way to manage GHB withdrawal. However, a detailed description
of the course of the GHB withdrawal syndrome is currently lacking. This study aimed to (1) describe
the course of GHB withdrawal symptoms over time, (2) assess the association between vital signs
and withdrawal symptoms, and (3) explore sex differences in GHB withdrawal. In this observational
multicenter study, patients with GHB use disorder (n = 285) were tapered off with pharmaceutical
GHB. The most reported subjective withdrawal symptoms (SWS) were related to cravings, fatigue,
insomnia, sweating and feeling gloomy. The most prevalent objective withdrawal symptoms (OWS)
were related to cravings, fatigue, tremors, sweating, and sudden cold/warm feelings. No association
between vital signs and SWS/OWS was found. Sex differences were observed in the severity and
prevalence of specific withdrawal symptoms. Our results suggest that the GHB withdrawal syndrome
under pharmaceutical GHB tapering does not strongly differ from withdrawal syndromes of other
sedative drugs. The lack of association between vital signs and other withdrawal symptoms, and the
relative stability of vitals over time suggest that vitals are not suitable for withdrawal monitoring. The
reported sex differences highlight the importance of a personalized approach in GHB detoxification.
Keywords: gamma-hydroxybutyric acid; GHB; addiction; withdrawal; dependence; detoxification;
abstinence; treatment; sex differences
1. Introduction
The repeated use of the recreational drug γ-hydroxybutyric acid (GHB) can lead to
GHB use disorder (GUD) [1,2]. Similar to other substance use disorders (SUDs), GUD is
characterized by a loss of control over GHB intake and physical dependence on GHB [3].
In 2019, the prevalence of GHB use in European countries varied from 0.1% in adults
(16–64 year old) to 1.7% among young adults (16–34 year old) [2]. Although GUD has a
relatively low prevalence compared to other SUDs, its societal and financial impact are
disproportionally high. GHB use is involved in ~12% of drug-related emergency care cases
in Europe, caused by accidental overdosing or severe withdrawal symptoms upon sudden
abstinence [2,4].
Due to the rapid onset of action (Tmax = 25–40 min) and the short half-life
(T 12 = 30–60 min) of GHB, patients with GUD typically consume GHB every 2–3 h to
prevent withdrawal symptoms [5,6]. Cessation of GHB use results in a severe withdrawal
syndrome, characterized by an erratic and fulminant course. Reported symptoms of
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GHB withdrawal are tremors, agitation, anxiety, hallucinations, psychoses and delir-
ium [6,7]. Abrupt GHB withdrawal without adequate treatment leads to delirium in
over 50% of cases [7].
Treatment of GHB withdrawal during detoxification aims to reduce the severity of
withdrawal symptoms. Two commonly used methods for GHB detoxification are ben-
zodiazepine tapering and the more extensively studied pharmaceutical GHB tapering.
Benzodiazepine administration increases GABAergic signaling through the GABAA recep-
tor, and requires dose regimens of up to six times per day [8,9]. In contrast, pharmaceutical
GHB activates both the GABAB and GHB receptor, and is administered to the patient every
two to three hours [10].
Some studies suggest that pharmaceutical GHB tapering is a safer method for detoxi-
fication compared to benzodiazepines [6,8]. This might be related to the complex pharma-
cological profile of GHB. Studies have shown that low doses of GHB primarily affect the
metabotropic GHB receptor, causing an increase in glutamatergic signaling and a decrease
in GABAergic signaling [11,12]. In contrast, high doses of GHB also activate the GABAB
receptor, decreasing glutamatergic signaling and increasing GABAergic signaling [13,14].
Benzodiazepines, acting at GABAA receptors, might therefore not sufficiently suppress
GABAB-mediated GHB withdrawal, leading to an increased risk for adverse events during
benzodiazepine detoxification, such as delirium [8].
Despite the existing evidence for the safety of pharmaceutical GHB tapering, several
important issues regarding this approach remain to be elucidated [6,15]. For instance,
little is known about the development of individual withdrawal symptoms over time
during GHB detoxification. Additionally, some suggest to base the speed of tapering on
the monitoring of vital signs, such as blood pressure and heart rate [16–18], whereas others
propagate the monitoring of (subjective) withdrawal symptoms [15,19]. Understanding the
development of individual withdrawal symptoms over time, and their relationship with
vital signs, could facilitate the effective dosing and monitoring of the detoxification process.
The GUD population is characterized by a substantial proportion of women of about
one third [6,20]. Women with SUDs are known to show higher rates of internalizing
psychiatric symptoms, such as depression and anxiety, whereas men with SUDs show
higher rates of externalizing symptoms, such as antisocial personality [21–23]. It has been
shown that women with GUD experience stronger withdrawal compared to men with
GUD [6]. However, detailed information on the exact nature of these sex differences
is lacking.
The aim of the current study is to further our understanding of the GHB withdrawal
syndrome, in order to improve medical treatment of this condition. We characterize the
course of the GHB withdrawal syndrome during inpatient pharmaceutical GHB detoxifi-
cation in a large database of clinical observations in patients with GUD. Specifically, we
analyze: 1. the course of individual withdrawal symptoms over time, 2. the association
between vital signs and subjective withdrawal symptoms, and 3. sex differences in the
course of the GHB withdrawal syndrome.
2. Materials and Methods
2.1. Study Design
We used data from two large observational multicenter studies in patients with GUD.
The main focus of these studies was to assess the safety of detoxification with pharma-
ceutical GHB, as published elsewhere [6,24]. Both studies had similar inclusion criteria,
treatment paradigms, and outcome measures. The Medical Ethical Research Committee
Twente and Central Committee on Research Involving Human Subjects approved the
study protocols and considered that the study did not fall under the scope of the Medical
Research Involving Human Subjects Act (WMO). The off-label use of pharmaceutical GHB
for GHB detoxification was approved by the Dutch Health Care Inspection.
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2.2. Participants
Inpatients being treated for GUD (n = 412) at one of the seven participating addiction
treatment centers in the Netherlands (Novadic-Kentron, Tactus, IrisZorg, Victas, Verslav-
ingszorg Noord-Nederland, Brijder and Mondriaan GGZ) were included between 2011
and 2015. Patients were between 18 and 60 years old. All patients were classified with
GHB dependence according to the Diagnostic and Statistical Manual of Mental Disorders
IV-TR [25] general criteria for psychoactive substance dependence. Patients were excluded
from the study if they could not speak or read the Dutch language, if they suffered from
a severe co-morbid psychiatric condition that required immediate attention (e.g., psy-
chosis, manic episodes, or suicidal ideation), or in the case of pregnancy [6]. Patients
were excluded from data analyses if they had less than three tapering days, or if their
GHB dose before admission was below 30 milliliters (since these patients should have
been treated ambulatory) or above 240 milliliters (since these patients showed an aberrant,
non-representative GHB withdrawal syndrome under pharmaceutical GHB tapering). The
threshold of >240 mL was determined by adding 2.5 SDs to the daily average consumption
volume. If patients were included in both monitors, data of the first treatment episode were
used. This resulted in a database of 285 complete, unique patients with GUD undergoing
inpatient GHB detoxification (Figure 1).
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2.3. Instruments
Demographics and other clinical data were obtained from chart reviews (admission
data, discharge data and the discharge summary). Measurements in the Addictions for
Triage and Evaluation (MATE) Section 1 was used to assess current substance use (past
30 days), lifetime substance use, and the classification of substance dependence according
to DSM-IV [26]. In Dutch addiction treatment centers, the MATE is the standard clinical
assessment tool, and has proven to have good psychometric quality [26]. The GHB ques-
tionnaire, specifically assessing the pattern of previous GHB use, was used in addition to
the MATE [6]. The GHB questionnaire consists of 23 parameters, including total years of
use, daily dose, volume per dose and time interval between doses. The questionnaire is
commonly used in Dutch addiction treatment centers that treat patients with GUD.
2.3.1. Subjective Withdrawal Scale
The subjective withdrawal scale consists of 33 items representing individual with-
drawal symptoms. Patients indicate to what degree they experience each symptom on a
5-point Likert scale (0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, 4 = extremely).
The subjective withdrawal scale is based on the format of the Subjective Opiate Withdrawal
Scale [27], extended with subjective withdrawal symptoms of other psychoactive sub-
stances as described in the DSM-IV-TR [25]. Its Dutch translation has good psychometric
properties in opioid-dependent inpatients [28].
2.3.2. Objective Withdrawal Scale
The objective withdrawal scale consists of 34 observable signs of withdrawal. It
is composed of symptoms included in the Objective Opiate Withdrawal Scale [27] and
objective withdrawal symptoms of other psychoactive substances as described in the DSM-
IV-TR [25]. The objective withdrawal scale is filled in by health professionals (mostly
nursing staff), where symptoms are classified as present (1) or absent (0). The objective and
subjective withdrawal scale have been reported in several previous studies assessing GHB
withdrawal [6,8], and are the standard GHB withdrawal assessment scales in addiction
treatment centers in the Netherlands. As a result, clinical staff are experienced with
applying these instruments in their daily routine. Furthermore, prior to the data collection
of both samples, all nursing staff received instructions and training in how to handle the
withdrawal scales.
2.3.3. Vitals
Vital signs (heart rate, systolic- and diastolic blood pressure) were measured by the
nursing staff. Vitals were annotated under the objective withdrawal scale.
2.4. Procedure
Upon admission to the addiction treatment center, information on GHB use and GUD
was acquired by trained study nurses through the above-mentioned questionnaires. The
detoxification procedure consisted of three phases: titration, tapering, and recovery. During
the titration phase, patients were treated with pharmaceutical GHB that was 70% of the
reported self-administered illicit GHB dose (based on an average ‘street’ concentration
of 650 mg/mL). The GHB dose was increased in the case of withdrawal and decreased
in the case of sedation, until the pharmaceutical GHB dose was found on which patients
were stable and experienced neither withdrawal nor sedation. This usually took between
one and two days, after which, the tapering phase started. During the tapering phase, the
GHB dose was lowered by 300 mg of the GHB per dose per day. The interval between
doses was usually two to three hours. Symptoms were assessed 30 min prior to each GHB
dose. The tapering phase lasted 11 days on average. The recovery phase started when
the pharmaceutical GHB was tapered to 0, which lasted six days on average. For a more
detailed description of the protocol, see Dijkstra et al. (2017) [6].
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2.5. Data Analysis
Demographics were summarized using descriptive statistics and compared between
men and women using one-way MANOVAs (GHB use characteristics (including age, age at
first GHB use, mean years of GHB use, mean days of GHB use, mean daily GHB dose, mean
interval between two GHB doses) and co-morbid substance use) and Pearson chi-square
test (medication).
To describe the general course of GHB withdrawal, we examined the first 11 days of
tapering, since the average tapering period lasted 10.3 days. Linear mixed model analysis
was performed to assess the development of total SWS/OWS scores over time. Mean daily
SWS/OWS scores were used as dependent variables.
We visualized symptom severity and prevalence using heat maps. The average relative
symptom severity and prevalence were calculated by dividing the average symptom score
on the respective scale by the maximum possible score on that scale. To examine the
development of individual withdrawal symptoms over time, we performed descriptive
statistics. Pearson correlation analysis was performed to assess the association of individual
withdrawal symptoms between both scales. Bonferroni corrections were applied to correct
for multiple comparisons.
Linear mixed model analysis was performed to assess the development of vital signs over
time. The mean daily scores of the vital parameters were used as dependent variables. Pearson
correlation analysis was performed to assess the association of vital signs with daily average
SWS/OWS scores. Bonferroni corrections were applied to correct for multiple comparisons.
Finally, to explore sex differences in the course of withdrawal symptoms over time,
we performed linear mixed model analysis. Daily average SWS and OWS scores were used
as the dependent variables, and sex was used as an independent variable. Sex differences
in the severity and prevalence of individual withdrawal symptoms were analyzed using
one-way MANOVA, using average scores per patient per symptom across the entire
tapering period.
ANOVAs, chi-square tests, correlations, heat map analyses and linear mixed model
analyses were carried out with the Statistical Package for the Social Sciences (SPSS) (25.0)
and with GraphPad Prism (9.0). Significance was set at p < 0.05.
3. Results
3.1. Demographics
Demographic characteristics of participants (n = 285) are presented in Table 1. Men and
women differed in GHB-related characteristics (Table 1: one-way MANOVA, F(6,174) = 2.227,
p < 0.05; Wilk’s λ = 0.929). Men included in the analysis were older and started using
GHB at a later age compared to women (Table 1: age (F(1,179) = 8.978, p < 0.01); age at first
GHB use (F(1,179) = 6.797, p < 0.01)). Men and women did not differ in rates of co-morbid
substance use or in the prevalence of medication use.
Table 1. Patients with GUD characteristics of unique patients (n = 285).
Characteristics Male (n = 206) Female (n = 79)
Sex 72.3% 27.7%
Mean age in years (SD) ** 29.34 (6.44) 26.63 (6.67)
Mean age at first GHB use (SD) ** 25.05 (6.67) 21.96 (6.62)
Mean years of GHB use (SD) 4.18 (2.62) 3.83 (2.96)
Mean days of GHB use in last 30 days (SD) 29.69 (1.74) 29.91 (0.71)
Mean daily GHB dose before admission in mL (SD) 92.01 (48.75) 76.44 (43.05)
Mean interval between two GHB doses in hours (SD) 2.30 (5.88) 1.85 (0.64)
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Table 1. Cont.
Characteristics Male (n = 206) Female (n = 79)
Mean number of days of co-morbid substance use in
last 30 days (SD)
Alcohol 4.95 (8.87) 2.96 (5.77)
Nicotine 20.97 (13.55) 23.04 (12.64)
Cannabis 6.68 (11.56) 5.73 (10.60)
Stimulants 5.46 (10.23) 5.35 (10.07)
Cocaine 2.11 (5.97) 1.64 (0.95)
Sedatives 8.16 (12.88) 8.87 (12.92)
Medication
Anti-psychotics 15.53% 12.66%
Beta blockers 3.88% 2.53%
Benzodiazepines 40.78% 41.77%
Sleep medication 17.48% 15.19%
Other 24.27% 29.11%
** = p < 0.01.
3.2. Development of Withdrawal Symptoms over Time during GHB Detoxification
The total SWS and OWS scores gradually decreased across the tapering phase (linear
mixed models, SWS: main effect of time, F(10,198) = 12.185, p < 0.0001; OWS, main effect of
time, F(10,209) = 9.639, p < 0.0001). The most severely experienced SWS were “craving”, “fa-
tigue”, “insomnia” and a “gloomy” and “slow, sluggish feeling” (Figure 2). The most often
reported OWS by nurses were “craving” and “fatigue”, next to the symptoms “shaking
hands”, “sweating” and a “sudden cold/warm feeling” (Figure 2).
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Figure 2. Average relative severit and rev l nce of subjective- and obj c ive withdrawal symptoms.
(a) Heat map of all 33 SWS over time for the first 11 detoxification days. Symptoms are ranked based
on the average severity of the symptom over all days for males and females combined. (b) Heat
map of all 34 OWS over time for the first 11 detoxification days. Symptoms are ranked based on the
average presence of the symptom over all days for males and females combined.
The SWS “muscle aches”, “muscle twitch s”, “tense , stressed f eling”, “experiencing
a fast heart rate” and “abdominal cramps” were most severe in the first part of detoxification
(first three days). Over the first four days, a >70% decrease in severity was reported for
these symptoms. In contrast, several SWS (“sweating”, “tremor”, “sleeps a lot”, and
“restless feeling”) remaine st ble over tim (<25% decrease in severity over 11 days). On
average, there were no SWS that became more severe during the tapering phase.
The OWS “sweating”, “sudden cold/warm feeling”, “muscle aches”, “tensed, stressed
feeling”, “shiv rs”, “having unpleasant dreams”, “hungry”, and “g osebumps” were
primarily present in the first part of detoxification (first 3 days). Over the first four days,
a >70% decrease in prevalence was observed for these symptoms. The OWS “tremor”,
“shaking hands”, “sleepy, sleeps”, “insomnia”, “restless” and “yawning” were consistently
present over time (<25% decrease in presence over 11 days). The OWS “yawning”, “insom-
nia”, “gloomy” and “visual hallucinations” were on some days more prevalent compared
to day 1. The majority of SWS and OWS that appeared on both scales showed a moderate
to strong correlation with the corresponding symptom on the other scale (r = 0.226 to 0.826,
p < 0.0015 after Bonferroni correction) (Table A1).
The average heart rate gradually increased over time during detoxification from 87.9
to 91.1 bpm (linear mixed models, heart rate: main effect of time: F(10,192) = 3.509, p < 0.001).
The average systolic and diastolic blood pressure gradually decreased over time from 132.5
to 127.3 mmHg, and from 84.1 to 80.4 mmHg, respectively (linear mixed models, systolic
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blood pressure main effect of time: F(10,196) = 5.848, p < 0.0001; diastolic blood pressure
main effect of time: F(10,183) = 10.095, p < 0.0001), as shown in Figure 3.
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3.3. Association between Vital Signs and Subjective- and Objective Symptoms of GHB Withdrawal
Overall, no correlations were observed between vital signs and daily average SWS
scores (Table A2) or between vital signs and daily average OWS scores after correction for
multiple testing (p > 0.0015), see Table A3.
3.4. Differences in GHB Withdrawal Syndrome between Men and Women
In contrast to what we expected, there was no difference in total SWS and OWS scores
between men and women across the tapering phase (Figure 4: linear mixed models, no
effect of sex), and both sexes showed a similar decrease in total OWS score over time
(Figure 4: linear mixed models, OWS no significant interaction). Men and women showed
a slightly different course of total SWS score over time (Figure 4: linear mixed models, SWS
time x sex interaction, F(10,198) = 2.038, p < 0.05).
One-way MANOVA showed that men and women differed in the severity of in-
dividual SWS (F(33,233) = 2550, p < 0.001; Wilk’s λ = 0.735). Specifically, women scored
higher on fear (F(1,265) = 4.531, p < 0.05), gloomy feeling (F(1,265) = 7.507, p < 0.01), yawning
(F(1,265) = 6.132, p < 0.05), goosebumps (F(1,265) = 6.272, p < 0.05), sweating (F(1,265) = 7.583,
p < 0.01), tearing eyes (F(1,265) = 6.863, p < 0.01), muscle aches (F(1,265) = 9.357, p < 0.01),
nausea (F(1,265) = 4.700, p < 0.05), craving (F(1,265) = 7.519, p < 0.01), sudden cold feelings
(F(1,265) = 13.248, p < 0.001), and sudden warm feelings (F(1,265) = 7.979, p < 0.01), whereas
men were more often reported to eat a lot during detoxification compared to women
(F(1,265) = 14.059, p < 0.001), see Figure 2).
One-way MANOVA showed that men and women differed in prevalence of indi-
vidual OWS (F(34,234) = 2.004, p < 0.01; Wilk’s λ = 0.774). Women showed more shivering
(F(1,267) = 16.046, p < 0.0001), sudden cold/warm feelings (F(1,267) = 5.664, p < 0.05, abdom-
inal cramps (F(1,267) = 6.665, p < 0.05), nausea (F(1,267) = 10.103, p < 0.01) and vomiting
(F(1,267) = 4.492, p < 0.05), while men showed more insomnia (F(1,267) = 5.024, p < 0.05) and
eating a lot (F(1,267) = 7.382, p < 0.01). Additionally, men showed a higher blood pressure
than women (Figure A1).
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Figure 4. Development of subjective- and objective withdrawal symptoms over time in males and females. (a) Development
of subjective withdrawal symptoms (SWS) during GHB detoxification, divided by sex. SWS are presented as the average
severity of all 33 measured SWS during the day (males n = 74–184, females n = 31–76). (b) Development of objective
withdrawal symptoms (OWS) during GHB toxification, divid d by sex. OWS are presented as th average presence of all
34 measured objective withdra al symptoms during the day (males n = 77–191, females n = 31–72). Data are presented as
mean ± SEM. #### = mai effect of time p < 0.0001; * = time x sex interaction p < 0.05.
4. Discussion
This study set out to analyze the course of the GHB withdrawal syndrome in patients
with GUD during inpatient detoxification with pharmaceutical GHB. The GHB withdrawal
syndrome was primarily characterized by sleep-related symptoms, mood-related symp-
toms and several physiological symptoms, including sweating and tremors. The majority
of symptoms steadily declined in severity over time, while some symptoms (e.g., tremors,
sleeping a lot) were not strongly affected by GHB tapering. Vital signs did not correlate
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with other withdrawal symptoms. Women showed a different pattern of withdrawal
symptoms compared to men.
The most prominent withdrawal symptoms that decreased over time include “crav-
ing”, “fatigue”, “insomnia”, “gloomy”, “slow, sluggish”, “sudden cold/warm feeling”,
“muscle aches” and “tensed, stressed”, and might represent the core symptoms of GHB
withdrawal. Other withdrawal symptoms that were frequently present during detoxifica-
tion include “sweating”, “tremor” and “restlessness”. Withdrawal syndromes of other seda-
tives, such as alcohol and benzodiazepine withdrawal, show overlap with symptoms seen
in this study, such as anxiety/fear, tremor, sweating, insomnia (alcohol/benzodiazepines),
restlessness and muscle twitches (benzodiazepines) [29,30]. Other characteristic alcohol
withdrawal symptoms such as hypertension, tachycardia, and fever were hardly seen in
our sample [31,32]. Similarly, severe GHB withdrawal symptoms such as epileptic seizures,
hallucinations and delirium, were rare in our sample, probably because GHB tapering
dampened the overall severity of withdrawal symptoms. Future studies should address
whether other withdrawal scales, for instance the Clinical Institute Withdrawal Assessment
for Alcohol (CIWA-Ar) tool, can also reliably be used to guide tapering [33]. Indeed, the
CIWA-Ar has also been used to assess GHB withdrawal in two case reports [34,35].
Several symptoms present at the start of detoxification were not strongly affected by
GHB tapering (“sweating”, “tremor”, “sleeps a lot”, ”sleepy”, “sleeps”, “restless feeling”,
”restless”, “yawning” and “shaking hands”). This may reflect a more long-term dysregu-
lation of autonomic processes, for instance, due to a chronically disrupted sleep pattern.
Several of these symptoms were also still present upon discharge of GHB detoxification
treatment, including “craving” and “insomnia”. The presence of several symptoms fol-
lowing detoxification, including sleep-related disturbances, might also contribute to the
high relapse rates seen with GUD, which is also observed with other SUDs such as alcohol,
cocaine and opioid use disorder [36]. Aftercare following detoxification should therefore
aim at reducing these symptoms that persist after detoxification, such as sleep-related
issues and cravings.
Contrary to other substance withdrawal syndromes, we did not find an association
between vital signs and objective or subjective GHB withdrawal symptoms [37,38]. In
several other substance withdrawal syndromes, vitals are associated with withdrawal
symptom severity and are therefore used as an indicator for overall withdrawal severity.
For instance, in alcohol, vital signs are used to determine titration and tapering regimes
during detoxification [3,38–40]. Our findings suggest that changes in vital signs during
GHB detoxification may not be suitable for the monitoring of GHB withdrawal severity.
Additionally, both the increase in heart rate (from 87.9 to 91.1 bpm on average) and the
decreases in systolic and diastolic blood pressure (from 132.5/84.1 to 127.3/80.4 mmHg on
average) we observed here were rather small and of little clinical relevance, despite being
statistically significant. Yet, with sudden GHB withdrawal, tachycardia and hypertension
are often observed [7]. Our results indicate that GHB tapering might have prevented a
derailment of vital signs, implicating that a change in withdrawal symptoms may precede
a derailment of vital signs during GHB detoxification, as also suggested by Beurmanjer
et al. (2020) [8].
Men and women showed different types of withdrawal symptoms. Specifically,
women scored higher on average on a large variety of (mainly subjective) individual
withdrawal symptoms. This is also observed with other SUDs such as opioids, cannabis and
nicotine [41–43]. The differences in GHB withdrawal symptoms between males and females
may be partially related to differences in co-occurring psychiatric conditions. Dijkstra et al.
(2017) showed that patients with GUD with higher baseline levels of depression, anxiety
and stress experienced higher levels of subjective withdrawal [6]. In addition, co-morbid
mood and anxiety disorders are more common in women with SUDs compared to men with
SUDs [21–23], possibly explaining the increased severity of several individual withdrawal
symptoms in women during GHB detoxification compared to men. In contrast to the
findings of Dijkstra et al. (2017), we did not find a difference in total SWS severity between
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men and women across the tapering phase [6]. This may be explained by the fact that
Dijkstra et al. (2017) included the titration-, tapering- and recovery days, whereas we
only focused on the tapering phase. The limited suppression of (co-morbid) symptoms
during titration and recovery days might account for the observed differences. The reported
differences between men and women suggest that women might benefit from more gradual
tapering strategies compared to men.
In the assessment of GHB withdrawal severity, both objective and subjective symptoms
were measured. There is a large overlap between the objective and subjective withdrawal
scales regarding the type of symptoms assessed. It can be questioned whether both scales
are required to obtain a complete picture of withdrawal severity. The current data show
that subjective withdrawal severity generally parallels clinical observations by nursing staff,
as also seen with, e.g., opioid withdrawal [28]. However, the subjective withdrawal scale
seems more sensitive to a change in withdrawal severity, probably as a result of the 5-point
Likert scale design compared to the dichotomous objective withdrawal scale. It might thus
be sufficient to focus on self-reported withdrawal severity to monitor GHB detoxification.
The current findings should be viewed in light of several study limitations. A relatively
high proportion of patients in our study showed co-morbid substance use (Table 1), possibly
contributing to the observed withdrawal symptoms. However, the observed prevalence of
co-morbid substance use is representative for the population of patients with GUD [44]. On
the one hand, the high rates of co-morbid substance use hamper firm conclusions about the
specific effects of GHB withdrawal. On the other hand, clinical reality is that people with
GUD often have co-morbid SUDs, thus making our observations clinically relevant [44].
The withdrawal scales used in this study were originally based on opioid withdrawal
scales [27], and complemented with other symptoms based on the DSM-IV [25]. Although
a total of 38 individual withdrawal signs and symptoms were assessed, it is still possible
that withdrawal symptoms that are unique for GHB withdrawal were not assessed with
the current withdrawal scales. Throughout detoxification, patients repeatedly mentioned
that they had an itchy feeling. This symptom may be considered to be included in the GHB
withdrawal scale.
During GHB detoxification, pharmacological treatment for co-morbid psychiatric
disorders, such as benzodiazepines, selective serotonin reuptake inhibitors (SSRIs) or
anti-psychotics, continued. We speculate this may have dampened the severity of GHB
withdrawal, possibly causing our results to be an underestimation of the severity of GHB
withdrawal compared to when only pharmaceutical GHB is provided, as also suggested
in previous reports [9,45]. The effects of other medications on the course of the GHB
withdrawal syndrome requires further study.
It is also important to note that the current findings do not generalize to other methods
for GHB detoxification, such as benzodiazepine tapering (different receptor systems), or
acute unassisted GHB detoxification (cold turkey). Severe withdrawal symptoms, such as
epileptic seizures and psychotic symptoms that were hardly observed here, might be more
common in such cases [7,8].
5. Conclusions
The GHB withdrawal syndrome during pharmaceutical GHB tapering is charac-
terized by a variety of symptoms that fade over time, and which are also commonly
observed during alcohol and benzodiazepine withdrawal. The observed lack of associ-
ation between vitals and subjective or objective withdrawal symptoms, and the limited
variation of vitals over time, question their relevance as an indicator for GHB withdrawal
severity during detoxification. Finally, women experience qualitatively different GHB
withdrawal symptoms during GHB detoxification compared to men. Our research suggests
that the subjective withdrawal scale may serve as a basis to personalize tapering speed
in order to minimize withdrawal severity, and account for sex differences in the GHB
withdrawal syndrome.
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Figure A1. Development of vital signs over time in males and females during the first 11 days of GHB tapering. Data 
presented as mean ± SEM. Error bars are not shown if they are shorter than the size of the symbol. # = main effect of sex, 
p < 0.05; ### = main effect of time, p < 0.001; #### = main effect of time/sex, p < 0.0001; * = time × sex interaction, p < 0.05. 
Table A1. Correlation between similar withdrawal symptoms measured with both the subjective- 
and objective withdrawal scale. 
SWS OWS Pearson’s r 
Craving Craving 0.602 *** 
Fatigue Fatigue 0.488 *** 
Insomnia Insomnia 0.479 *** 
Gloomy feeling Gloomy 0.532 *** 
Slow, sluggish feeling Slow, sluggish 0.403 *** 
Sweating Sweating 0.534 *** 
Tremor Tremor/shaking hands 0.313 ***/0.409 *** 
Sudden cold feeling Sudden cold/warm feeling 0.533 *** 
Muscle aches Muscle aches 0.629 *** 
Sudden warm feeling Sudden cold/warm feeling 0.528 *** 
Restless feeling Restless 0.443 *** 
Tensed, stressed feeling Tensed, stressed 0.511 *** 
Having lively dreams Having lively dreams 0.679 *** 
Eats a lot Eats a lot 0.512 *** 
Fear Fear 0.660 *** 
Yawning Yawning 0.318 *** 
Slow in movements Slow in movements 0.403 *** 
Having unpleasant dreams Having unpleasant dreams 0.687 *** 
Hungry Hungry 0.470 *** 
Muscle twitches Muscle twitches 0.516 *** 
Sleeps a lot Sleepy/sleeps 0.399 *** 
Goosebumps Goosebumps 0.370 *** 
Experience a fast heart rate Heart rate (vital sign) 0.370 *** 
Running nose Running nose 0.461 *** 
Abdominal cramps Abdominal cramps 0.564 *** 
Diarrhea Diarrhea 0.800 *** 
Tearing eyes Tearing eyes 0.162 NS 
Nausea Nausea/Nauseous 0.479 ***/0.657 *** 
Vomiting Vomiting 0.226 ** 
Figure A1. Development of vital signs over time in males and females during the first 11 days of GHB tapering. Data
presented as ean ± SE . Error bars are not shown if they are shorter than the size of the sy bol. # = ain effect of sex,
. ; i effect f ti e, . ; ### = main effect of ti e/sex, p < . 01; * = time × sex interaction, p < 0.05.
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Table A1. Correlation between similar withdrawal symptoms measured with both the subjective-
and objective withdrawal scale.
SWS OWS Pearson’s r
Craving Craving 0.602 ***
Fatigue Fatigue 0.488 ***
Insomnia Insomnia 0.479 ***
Gloomy feeling Gloomy 0.532 ***
Slow, sluggish feeling Slow, sluggish 0.403 ***
Sweating Sweating 0.534 ***
Tremor Tremor/shaking hands 0.313 ***/0.409 ***
Sudden cold feeling Sudden cold/warm feeling 0.533 ***
Muscle aches Muscle aches 0.629 ***
Sudden warm feeling Sudden cold/warm feeling 0.528 ***
Restless feeling Restless 0.443 ***
Tensed, stressed feeling Tensed, stressed 0.511 ***
Having lively dreams Having lively dreams 0.679 ***
Eats a lot Eats a lot 0.512 ***
Fear Fear 0.660 ***
Yawning Yawning 0.318 ***
Slow in movements Slow in movements 0.403 ***
Having unpleasant dreams Having unpleasant dreams 0.687 ***
Hungry Hungry 0.470 ***
Muscle twitches Muscle twitches 0.516 ***
Sleeps a lot Sleepy/sleeps 0.399 ***
Goosebumps Goosebumps 0.370 ***
Experience a fast heart rate Heart rate (vital sign) 0.370 ***
Running nose Running nose 0.461 ***
Abdominal cramps Abdominal cramps 0.564 ***
Diarrhea Diarrhea 0.800 ***
Tearing eyes Tearing eyes 0.162 NS
Nausea Nausea/Nauseous 0.479 ***/0.657 ***
Vomiting Vomiting 0.226 **
Auditory hallucinations Auditory hallucinations 0.826 ***
Visual hallucinations Visual hallucinations 0.725 ***




Correlation is significant if p < 0.0015 (Bonferroni correction, 2-tailed). ** = p < 0.001; *** = p < 0.0001;
NS = non-significant.
Table A2. Daily average subjective withdrawal symptoms correlated with vitals.
Heart Rate Systolic BloodPressure
Diastolic Blood
Pressure N
Tapering day 1 0.164 −0.035 0.003 242
Tapering day 2 0.137 −0.078 0.038 234
Tapering day 3 0.159 −0.170 −0.023 239
Tapering day 4 0.103 −0.137 0.011 219
Tapering day 5 0.173 −0.089 −0.013 213
Tapering day 6 0.159 −0.094 0.016 203
Tapering day 7 0.127 −0.093 0.002 169
Tapering day 8 0.190 −0.006 0.051 152
Tapering day 9 0.193 −0.107 0.100 138
Tapering day 10 0.071 −0.053 0.007 116
Tapering day 11 0.167 −0.036 0.171 98
Shown values are Pearson r.
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Table A3. Daily average objective withdrawal symptoms correlated with vitals.
Heart Rate Systolic Blood Pressure Diastolic Blood Pressure N
Tapering day 1 0.141 −0.021 0.046 263
Tapering day 2 0.133 −0.079 0.030 254
Tapering day 3 0.123 −0.005 0.086 255
Tapering day 4 0.050 −0.101 0.039 241
Tapering day 5 0.155 −0.081 0.033 233
Tapering day 6 0.055 −0.078 0.018 219
Tapering day 7 0.065 −0.091 0.037 185
Tapering day 8 0.114 0.047 0.134 168
Tapering day 9 0.172 −0.063 0.036 150
Tapering day 10 −0.040 −0.021 0.078 128
Tapering day 11 0.063 −0.043 0.157 108
Shown values are Pearson r.
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